[Advances in the study on antineoplastic action of realgar].
Pan
Bingli
B
Institute of Materia Medica, Huazhong University of Science and Technology, Wuhan 430074
Xu
Lingyun
L
Yang
Xiangliang
X
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology; D008419:Materia Medica / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010087:Oxides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001152:Arsenicals; D008419:Materia Medica; D010087:Oxides; D000077237:Arsenic Trioxide